Navigation Links
Ondine Biomedical CEO Carolyn Cross Appointed Treasurer of International Photodynamic Association
Date:6/4/2013

Vancouver, British Columbia (PRWEB) June 04, 2013

The International Photodynamic Association (IPA) has appointed Carolyn Cross, founder and CEO of Ondine Biomedical as incoming IPA Treasurer. She will be replacing Dr. Tayyaba Hasan, Professor of Dermatology Wellman Center of Photomedicine, Harvard University, and Board Member of the IPA, in this position. Carolyn Cross was recently the Plenary Session Speaker at the 2013 World Congress of the International Photodynamic Association in Seoul, South Korea, representing the field of work in Photodisinfection; also known as antimicrobial Photodynamic Therapy or aPDT. Ondine Biomedical is the global leader in the design and development of Photodisinfection based therapies, and is involved with all aspects of technology, product and clinical development through to commercialization of photodisinfection products.

“The IPA represents an extraordinary group of scientists and clinical researchers who are advancing the field of PDT around the world. It is an honour to serve this community and look forward to working with the newly appointed Secretary of the IPA, Professor Sam Eljamel, University of Dundee Scotland, who will be hosting the 2017 World Congress in Scotland," says Carolyn Cross upon her appointment.

Founded in 1986, the International Photodynamic Association was created to promote the study of diagnosis and treatment using light and photosensitisers, to disseminate such information to the members of the IPA, the medical community, and the general public. The IPA organizes an International Congress every two years to highlight leading research activities in the clinical and basic research aspects of PDT.

Carolyn Cross is the founder and CEO of Ondine Biomedical Inc. and has over 18 years direct experience working with early stage companies and has 25 years of experience with public market securities. Additionally, she currently serves on a number of Boards including the Canadian Foundation of Innovation (CFI), the International Photodynamic Association and the Faculty of Dentistry, McGill University. She is a Founding Member of the BC Women's Economic Advisory Council and the Ernst & Young Global Women in Business Advisory Council (GWBAC).

Earlier in her career, Carolyn Cross was portfolio manager, responsible for managing pension, pooled, mutual and private client funds as a Vice President with Royal Bank Investment Management Inc., the fund management arm of the Royal Bank of Canada. Carolyn Cross is a currently a member of the Women’s Presidents Organization, the International Women’s Forum, the Professional Women's Network, the Toronto Society of Financial Analysts, the Society for Canadian Women in Science and Technology, and the Association for Professionals In Infection Control and Epidemiology.

About Ondine Biomedical Inc.

Ondine is an incubator, developing non-antibiotic therapies based on Photodisinfection technology for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with USA Research and Development laboratories in Bothell, Washington and Minneapolis, Minnesota. Please visit the Company website at: http://www.ondinebio.com and Blog at: http://www.ondineblog.com. For further information please contact us at: Ondine Biomedical Inc. info(at)ondinebio(dot)com

Read the full story at http://www.prweb.com/releases/CarolynCross/InternationalPhotodynamic/prweb10796873.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ondine's CEO Carolyn Cross to be a Plenary Session Speaker at 14th World Congress of International Photodynamic Association
2. Ondine Biomedical’s MRSAID(TM) Technology Demonstrates Successful Results in Reducing Surgical Site Infections
3. Arteriocyte announces Launch of Compass Biomedical
4. Regenesis Biomedical Names Scott Brooks Chief Executive Officer
5. Premier Biomedical CEO Interviewed by The Wall Street Transcript
6. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
7. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
8. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
9. Fourth Annual Bay Area Biomedical Device Conference: March 27th, 2013 at San Jose State University
10. Foundation for the NIH Announces Lurie Prize Recognizing Outstanding Achievement by a Young Biomedical Scientist
11. ABIA Hires Biomedical Executive, Serial Entrepreneur as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September ... ... LLC (IPS), a leading global provider of engineering, architecture, project controls, construction ... of prefabricated cleanrooms, today announced the unveiling of the iCON™ brand which ...
(Date:9/20/2017)... ... September 20, 2017 , ... Foresight Institute, a leading ... transformative technologies, announced the winners for the 2017 Foresight Institute Feynman Prizes.These are ... nanotechnology/molecular manufacturing. , Established in 1993 and named in honor of pioneer physicist ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... largest group of funded early-stage tech companies. “Grit” author Angela Duckworth and her ... joining the ic@3401 community is Cooley, an international law firm with decades of ...
(Date:9/19/2017)... 19, 2017 ValGenesis Inc., the global leader ... to announce the strategic partnership with VTI Life Sciences ... validation services using the latest technology available in the ... clients with efficient and cost-effective validation services using ValGenesis ... the ValGenesis VLMS system. ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):